ADMINISTRATION ROUTES:
PO, IV
ALTERNATIVE NAMES:
Apo-Ranitidine, Zantac, Peptisoothe
ICU INDICATIONS:
- Ulcer prophylaxis
PRESENTATION AND ADMINISTRATION:
IV:
Dilute 50 mg dose to 20 mL with compatible IV fluid and administer into side arm over at least 2 minutes.
Compatible with the following IV fluids: 0.9% sodium chloride, 5% and 10% dextrose, Glucose & Sodium Chloride, Hartmann’s
Store at room temperature
PO:
Tablets
Apo-Ranitidine 150 mg tablets (white), Arrow Ranitidine 150 mg tablets (white), Zantac relief tablets (150 mg)
Oral solution:
Peptisoothe 150 mg/10 mL
Zantac Syrup 150 mg/10 mL
DOSAGE:
PO:
150 mg 8 - 12 hrly or 300 mg nocte
IV:
50 mg TDS
DOSAGE IN RENAL FAILURE AND RENAL REPLACEMENT THERAPY:
Dose in renal impairment
| GFR (ml/min) | DOSE |
|---|---|
| <10 | 50-100% of normal dose |
| 10-20 | dose as in normal renal function |
| >20-50 | dose as in normal renal function |
Dose in renal replacement therapy
| MODALITY | DOSE |
|---|---|
| CAPD | 50-100% of normal dose |
| HD | 50-100% of normal dose |
| CVVHDF | dose as in normal renal function |
DOSAGE IN PAEDIATRICS:
IV:
1 mg/kg TDS
PO:
2 - 4 mg/kg 8 - 12 hrly
CLINICAL PHARMACOLOGY:
Ranitidine is a selective, competitive antagonist of histamine at H2-receptor sites
CONTRAINDICATIONS:
- Hypersensitivity to ranitidine
WARNINGS:
Nil
PRECAUTIONS:
General:
Nil
Laboratory Tests:
No tests in addition to routine ICU tests are required
Drug/Laboratory Test Interactions:
None known
IMPORTANT DRUG INTERACTIONS IN ICU:
None of note
ADVERSE REACTIONS:
Body as a Whole:
Hypersensitivity reactions (e.g. fever, bronchospasm, anaphylactic shock, rash, eosinophilia)
Central nervous system.
Malaise, dizziness, somnolence, insomnia, vertigo, mental confusion, depression and hallucinations
Cardiovascular system.
Tachycardia, bradycardia, premature ventricular beats, A-V block and asystole
Gastrointestinal system:
Constipation, diarrhoea, nausea/ vomiting, abdominal discomfort/ pain, hepatitis, pancreatitis
Musculoskeletal system:
Rare reports of arthralgias and myalgia
Haematological system:
Agranulocytosis or pancytopaenia, sometimes with marrow hypoplasia or aplasia, have been reported
Dermatological system:
Rash including rare cases of mild erythema multiforme. Rare cases of vasculitis have been reported